Pharsight

Drug Patents owned by Merck Sharp Dohme

1. List of Belsomra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7951797 MERCK SHARP DOHME Substituted diazepan orexin receptor antagonists
Nov, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098892 MERCK SHARP DOHME Solid dosage formulations of an orexin receptor antagonist
May, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
M (M) Jan 29, 2023

Drugs and Companies using SUVOREXANT ingredient

Market Authorisation Date: 13 August, 2014

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

More Information on Dosage

BELSOMRA family patents

12

United States

4

Australia

4

Russia

4

China

4

Japan

3

Korea, Republic of

3

European Union

2

Mexico

2

Argentina

2

Brazil

2

Chile

2

Taiwan, Province of China

2

Ukraine

2

Canada

1

South Africa

1

Denmark

1

El Salvador

1

Hong Kong

1

Slovenia

1

Morocco

1

Norway

1

Costa Rica

1

Colombia

1

Croatia

1

Honduras

1

Portugal

1

Cyprus

1

Malaysia

1

Spain

1

Peru

1

Poland

1

Dominican Republic

1

RS

1

Ecuador

1

Nicaragua

1

New Zealand

2. List of Clarinex D 24 Hour drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7820199 MERCK SHARP DOHME Stable extended release oral dosage composition
Mar, 2022

(1 year, 5 days ago)

US6979463 MERCK SHARP DOHME Stable extended release oral dosage composition
Mar, 2022

(1 year, 5 days ago)

US7820199

(Pediatric)

 MERCK SHARP DOHME Stable extended release oral dosage composition
Sep, 2022

(6 months ago)

Drugs and Companies using DESLORATADINE; PSEUDOEPHEDRINE SULFATE ingredient

Market Authorisation Date: 03 March, 2005

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

CLARINEX D 24 HOUR family patents

4

Australia

4

United States

3

China

3

Japan

2

Saudi Arabia

2

Russia

2

Korea, Republic of

2

European Union

1

Israel

1

South Africa

1

Denmark

1

Slovakia

1

Turkey

1

Mexico

1

Austria

1

Egypt

1

Hong Kong

1

Slovenia

1

Hungary

1

Norway

1

Germany

1

Argentina

1

Singapore

1

Brazil

1

Colombia

1

Portugal

1

Cyprus

1

Indonesia

1

Malaysia

1

Spain

1

Peru

1

Poland

1

Czech Republic

1

Taiwan, Province of China

1

Ecuador

1

Canada

1

New Zealand

3. List of Dutrebis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7820660 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(22 days from now)

US7169780 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(6 months from now)

US7754731 MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Mar, 2029

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7435734 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(5 months ago)

US7217713 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(5 months ago)

US7217713

(Pediatric)

 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(18 days from now)

US7435734

(Pediatric)

 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(18 days from now)

US7169780

(Pediatric)

 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(1 year, 1 day from now)

US7754731

(Pediatric)

 MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Sep, 2029

(6 years from now)

Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 06 February, 2015

Treatment: Treatment of hiv-1 infection

Dosage: TABLET;ORAL

More Information on Dosage

DUTREBIS family patents

12

United States

4

Norway

4

China

3

Austria

3

Germany

3

Spain

3

Korea, Republic of

3

European Union

2

Israel

2

South Africa

2

Denmark

2

Mexico

2

Australia

2

Hong Kong

2

Slovenia

2

Hungary

2

Argentina

2

Brazil

2

Croatia

2

Portugal

2

Poland

2

Georgia

2

Ukraine

2

Japan

EA

2

EA

2

Canada

2

New Zealand

2

ME

1

Lithuania

1

Morocco

1

Costa Rica

1

Colombia

1

Cyprus

YU

1

Yugoslavia

1

Malaysia

1

Netherlands

1

Peru

1

Iceland

1

Taiwan, Province of China

1

Nicaragua

1

United Kingdom

1

Luxembourg

1

RS

1

Tunisia

4. List of Isentress drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169780 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(6 months from now)

US7754731 MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Mar, 2029

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7217713 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(5 months ago)

US7435734 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(5 months ago)

US7217713

(Pediatric)

 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(18 days from now)

US7435734

(Pediatric)

 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(18 days from now)

US7169780

(Pediatric)

 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(1 year, 1 day from now)

US7754731

(Pediatric)

 MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Sep, 2029

(6 years from now)

US9649311 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Oct, 2030

(7 years from now)

US9649311

(Pediatric)

 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Apr, 2031

(8 years from now)

US10772888 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Mar, 2032

(8 years from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 21 December, 2011

Treatment: Treatment of hiv infection; Treatment of hiv-1 infection

Dosage: TABLET, CHEWABLE;ORAL

How can I launch a generic of ISENTRESS before it's patent expiration?
More Information on Dosage

ISENTRESS family patents

17

United States

6

China

5

European Union

4

Norway

4

Spain

4

Korea, Republic of

4

Japan

4

New Zealand

3

Israel

3

South Africa

3

Denmark

3

Austria

3

Mexico

3

Australia

3

Slovenia

3

Hungary

3

Germany

3

Brazil

3

Croatia

3

Portugal

3

Poland

3

Canada

2

Hong Kong

2

Lithuania

2

Argentina

2

Colombia

2

Malaysia

2

Georgia

2

Ukraine

2

RS

EA

2

EA

2

ME

1

India

1

Russia

1

Morocco

1

Costa Rica

1

Cyprus

YU

1

Yugoslavia

1

Netherlands

1

Peru

1

Iceland

1

Taiwan, Province of China

1

United Kingdom

1

Nicaragua

1

Luxembourg

1

Tunisia

5. List of Janumet drug patents

JANUMET's oppositions filed in EPO
JANUMET Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(8 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(8 months ago)

US7125873

(Pediatric)

 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(2 months ago)

US6699871

(Pediatric)

 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(2 months ago)

US7326708

(Pediatric)

 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(4 years from now)

US8414921 MERCK SHARP DOHME Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Jul, 2028

(5 years from now)

US8414921

(Pediatric)

 MERCK SHARP DOHME Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Jan, 2029

(5 years from now)

Exclusivity Exclusivity Expiration
M (M) Dec 4, 2023
Pediatric Exclusivity (PED) Jun 4, 2024

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 30 March, 2007

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin; Method of treating type 2 diabetes mellitus by administering a dipeptidyl p...

Dosage: TABLET;ORAL

How can I launch a generic of JANUMET before it's patent expiration?
More Information on Dosage

JANUMET family patents

17

United States

6

European Union

5

Norway

5

Germany

4

China

4

Japan

3

Israel

3

Denmark

3

Austria

3

Australia

3

Argentina

3

Portugal

3

Spain

3

Korea, Republic of

3

Iceland

3

Georgia

EA

3

EA

3

Canada

2

South Africa

2

Mexico

2

Hong Kong

2

Slovenia

2

Jordan

2

Hungary

2

Morocco

2

Costa Rica

2

Croatia

2

Brazil

2

Cyprus

YU

2

Yugoslavia

2

Malaysia

2

Netherlands

2

Peru

2

Dominican Republic

2

Poland

2

Taiwan, Province of China

2

Ecuador

2

Luxembourg

2

Ukraine

2

New Zealand

2

ME

1

Lithuania

1

Belgium

1

Colombia

1

Bulgaria

1

Tunisia

6. List of Janumet Xr drug patents

JANUMET XR's oppositions filed in EPO
JANUMET XR Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(8 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(8 months ago)

US6699871

(Pediatric)

 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(2 months ago)

US7125873

(Pediatric)

 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(2 months ago)

US7326708

(Pediatric)

 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M (M) Dec 4, 2023
Pediatric Exclusivity (PED) Jun 4, 2024

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 02 February, 2012

Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JANUMET XR before it's patent expiration?
More Information on Dosage

JANUMET XR family patents

14

United States

5

Norway

5

Germany

5

European Union

3

Israel

3

Denmark

3

Austria

3

Argentina

3

Portugal

3

Spain

3

Korea, Republic of

3

Iceland

3

China

3

Georgia

EA

3

EA

2

South Africa

2

Mexico

2

Australia

2

Hong Kong

2

Slovenia

2

Jordan

2

Hungary

2

Morocco

2

Costa Rica

2

Croatia

2

Brazil

2

Cyprus

YU

2

Yugoslavia

2

Malaysia

2

Netherlands

2

Peru

2

Dominican Republic

2

Poland

2

Taiwan, Province of China

2

Ecuador

2

Luxembourg

2

Ukraine

2

Japan

2

Canada

2

New Zealand

2

ME

1

Lithuania

1

Belgium

1

Colombia

1

Bulgaria

1

Tunisia

7. List of Januvia drug patents

JANUVIA's oppositions filed in EPO
JANUVIA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(8 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(8 months ago)

US6699871

(Pediatric)

 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(2 months ago)

US7125873

(Pediatric)

 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(2 months ago)

US7326708

(Pediatric)

 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M (M) Dec 4, 2023
Pediatric Exclusivity (PED) Feb 12, 2023

Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 16 October, 2006

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with a ppar-gamma agonist; Method of treating type 2 diabetes mellitus by administering ...

Dosage: TABLET;ORAL

How can I launch a generic of JANUVIA before it's patent expiration?
More Information on Dosage

JANUVIA family patents

14

United States

5

Norway

5

Germany

5

European Union

3

Israel

3

Denmark

3

Austria

3

Argentina

3

Portugal

3

Spain

3

Korea, Republic of

3

Iceland

3

China

3

Georgia

EA

3

EA

2

South Africa

2

Mexico

2

Australia

2

Hong Kong

2

Slovenia

2

Jordan

2

Hungary

2

Morocco

2

Costa Rica

2

Croatia

2

Brazil

2

Cyprus

YU

2

Yugoslavia

2

Malaysia

2

Netherlands

2

Peru

2

Dominican Republic

2

Poland

2

Taiwan, Province of China

2

Ecuador

2

Luxembourg

2

Ukraine

2

Japan

2

Canada

2

New Zealand

2

ME

1

Lithuania

1

Belgium

1

Colombia

1

Bulgaria

1

Tunisia

8. List of Juvisync drug patents

JUVISYNC's oppositions filed in EPO
JUVISYNC Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(8 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Apr, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168637 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes
Jun, 2022

(9 months ago)

US7125873 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(8 months ago)

US7125873

(Pediatric)

 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(2 months ago)

US6699871

(Pediatric)

 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(2 months ago)

US7326708

(Pediatric)

 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Oct, 2026

(3 years from now)

Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate; Method of treating type 2 diabetes mellitus in patients for whom treatm...

Dosage: TABLET;ORAL

More Information on Dosage

JUVISYNC family patents

14

United States

5

Norway

5

Germany

5

European Union

3

Israel

3

Denmark

3

Austria

3

Argentina

3

Portugal

3

Spain

3

Korea, Republic of

3

Iceland

3

China

3

Georgia

EA

3

EA

2

South Africa

2

Mexico

2

Australia

2

Hong Kong

2

Slovenia

2

Jordan

2

Hungary

2

Morocco

2

Costa Rica

2

Croatia

2

Brazil

2

Cyprus

YU

2

Yugoslavia

2

Malaysia

2

Netherlands

2

Peru

2

Dominican Republic

2

Poland

2

Taiwan, Province of China

2

Ecuador

2

Luxembourg

2

Ukraine

2

Japan

2

Canada

2

New Zealand

2

ME

1

Lithuania

1

Belgium

1

Colombia

1

Bulgaria

1

Tunisia

9. List of Noxafil drug patents

NOXAFIL's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US10117951 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US9750822 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US9358297 MERCK SHARP DOHME Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin
Jun, 2031

(8 years from now)

US9023790 MERCK SHARP DOHME Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin
Jul, 2031

(8 years from now)

US9493582 MERCK SHARP DOHME Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(9 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) May 31, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2028
New Indication (I) Jun 17, 2024

Drugs and Companies using POSACONAZOLE ingredient

Market Authorisation Date: 13 March, 2014

Treatment: Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of a...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of NOXAFIL before it's patent expiration?
More Information on Dosage

NOXAFIL family patents

19

United States

9

Japan

7

China

6

European Union

5

Mexico

5

Korea, Republic of

4

Australia

4

Canada

3

Russia

2

Israel

2

Hong Kong

2

Brazil

1

Denmark

1

Lithuania

1

Slovenia

1

Hungary

1

Croatia

1

Portugal

1

Spain

1

Poland

1

RS

EA

1

EA

1

New Zealand

10. List of Prevymis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46791 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(1 year, 1 month from now)

US8513255 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(1 year, 1 month from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603384 MERCK SHARP DOHME Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
Feb, 2033

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 8, 2024

Drugs and Companies using LETERMOVIR ingredient

Market Authorisation Date: 08 November, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PREVYMIS family patents

5

European Union

4

United States

3

Hungary

3

Germany

3

China

2

Israel

2

South Africa

2

Denmark

2

Mexico

2

Australia

2

Hong Kong

2

Slovenia

2

Morocco

2

Norway

2

Colombia

2

Brazil

2

Portugal

2

Malaysia

2

Spain

2

Korea, Republic of

2

Poland

2

Chile

2

Ukraine

2

Japan

2

Canada

2

New Zealand

1

Austria

1

Egypt

1

Lithuania

1

Russia

1

Philippines

1

Uruguay

1

Argentina

1

Honduras

1

Singapore

1

Croatia

1

Netherlands

1

Peru

1

India

1

Ecuador

1

RS

1

Taiwan, Province of China

EA

1

EA

1

Tunisia

1

ME

11. List of Segluromet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9308204 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

US9439902 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M (M) Sep 17, 2024

Drugs and Companies using ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage

SEGLUROMET family patents

13

United States

3

Korea, Republic of

2

Israel

2

South Africa

2

Denmark

IB

2

IB

2

Australia

2

Hong Kong

2

Slovenia

2

Costa Rica

AP

2

AP

2

Croatia

2

Portugal

2

Cyprus

2

Spain

2

Poland

2

RS

2

China

2

Ecuador

2

Georgia

2

Ukraine

2

Japan

EA

2

EA

2

Canada

2

New Zealand

2

ME

2

European Union

1

El Salvador

1

Austria

1

Mexico

1

Lithuania

1

Hungary

1

Morocco

1

Uruguay

1

Norway

1

Cuba

1

Argentina

1

Colombia

1

Brazil

1

Honduras

1

Malaysia

1

Netherlands

1

Peru

1

Dominican Republic

1

Chile

1

Taiwan, Province of China

1

Nicaragua

1

Tunisia

1

Panama

12. List of Steglatro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M (M) Sep 17, 2024

Drugs and Companies using ERTUGLIFLOZIN ingredient

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

How can I launch a generic of STEGLATRO before it's patent expiration?
More Information on Dosage

STEGLATRO family patents

3

United States

2

Israel

2

Hong Kong

2

Korea, Republic of

2

China

1

South Africa

1

Denmark

IB

1

IB

1

El Salvador

1

Austria

1

Mexico

1

Australia

1

Slovenia

1

Lithuania

1

Morocco

1

Hungary

1

Uruguay

1

Norway

1

Costa Rica

1

Cuba

AP

1

AP

1

Argentina

1

Colombia

1

Croatia

1

Brazil

1

Honduras

1

Portugal

1

Cyprus

1

Malaysia

1

Spain

1

Netherlands

1

Peru

1

Poland

1

Dominican Republic

1

Chile

1

RS

1

Taiwan, Province of China

1

Nicaragua

1

Ecuador

1

Georgia

1

Ukraine

1

Japan

EA

1

EA

1

Canada

1

Tunisia

1

Panama

1

New Zealand

1

ME

1

European Union

13. List of Steglujan drug patents

STEGLUJAN's oppositions filed in EPO
STEGLUJAN Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(8 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(3 years from now)

US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6699871

(Pediatric)

 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(2 months ago)

US7326708

(Pediatric)

 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(4 years from now)

US9439901 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

US9308204 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M (M) Sep 17, 2024

Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage

STEGLUJAN family patents

27

United States

7

European Union

6

Norway

6

Korea, Republic of

5

Israel

5

Denmark

5

Germany

5

Portugal

5

Spain

5

China

5

Georgia

EA

5

EA

4

South Africa

4

Austria

4

Australia

4

Hong Kong

4

Slovenia

4

Costa Rica

4

Argentina

4

Croatia

4

Cyprus

4

Poland

4

Ecuador

4

Ukraine

4

Japan

4

Canada

4

New Zealand

4

ME

3

Mexico

3

Hungary

3

Morocco

3

Brazil

3

Malaysia

3

Netherlands

3

Peru

3

Dominican Republic

3

Iceland

3

Taiwan, Province of China

IB

2

IB

2

Lithuania

2

Jordan

AP

2

AP

2

Colombia

YU

2

Yugoslavia

2

RS

2

Luxembourg

2

Tunisia

1

El Salvador

1

Belgium

1

Uruguay

1

Cuba

1

Honduras

1

Chile

1

Nicaragua

1

Bulgaria

1

Panama

14. List of Temodar drug patents

TEMODAR's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7786118 MERCK SHARP DOHME Pharmaceutical formulations of antineoplastic agents
Feb, 2023

(a month ago)

US8623868 MERCK SHARP DOHME Processes of making and using pharmaceutical formulations of antineoplastic agents
Feb, 2023

(a month ago)

US6987108 MERCK SHARP DOHME Pharmaceutical formulations of antineoplastic agents and processes of making and using the same
Sep, 2023

(5 months from now)

Drugs and Companies using TEMOZOLOMIDE ingredient

Market Authorisation Date: 27 February, 2009

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

TEMODAR family patents

11

United States

3

Argentina

2

China

2

Japan

2

Canada

2

European Union

1

South Africa

1

Denmark

1

Austria

1

Mexico

1

Australia

1

Hong Kong

1

Slovenia

1

Norway

1

Germany

1

Singapore

1

Brazil

1

Portugal

1

Cyprus

1

Spain

1

Korea, Republic of

1

Poland

1

New Zealand

15. List of Verquvo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10736896 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

US8420656 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

US9604948 MERCK SHARP DOHME Process for preparing substituted 5-fluoro-1H-pyrazolopyridines
Nov, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921377 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

US11439642 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

US9993476 MERCK SHARP DOHME Substituted 5-flouro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 19, 2026

Drugs and Companies using VERICIGUAT ingredient

NCE-1 date: 2025-01-19

Market Authorisation Date: 19 January, 2021

Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and eject...

Dosage: TABLET;ORAL

More Information on Dosage

VERQUVO family patents

16

United States

11

European Union

6

Hungary

6

Taiwan, Province of China

6

Japan

EA

6

EA

5

Israel

5

Denmark

5

Australia

5

Slovenia

5

Costa Rica

5

Singapore

5

Croatia

5

Spain

5

Korea, Republic of

5

Poland

5

RS

5

China

5

Ukraine

5

Canada

5

New Zealand

4

Lithuania

4

Hong Kong

4

Cuba

4

Brazil

4

Portugal

4

Dominican Republic

4

Peru

4

Chile

3

South Africa

3

Mexico

3

Morocco

3

Uruguay

3

Malaysia

3

Tunisia

2

Philippines

2

Colombia

2

Argentina

2

Guatemala

2

Cyprus

2

Ecuador

2

ME

1

Turkey

1

Jordan

1

Norway

AP

1

AP

1

Germany

1

Netherlands

16. List of Victrelis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43298 MERCK SHARP DOHME Peptides as NS3-serine protease inhibitors of hepatitis C virus
Dec, 2024

(1 year, 8 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119602 MERCK SHARP DOHME Administration of HCV protease inhibitors in combination with food to improve bioavailability
Mar, 2027

(3 years from now)

US7772178 MERCK SHARP DOHME Pharmaceutical formulations and methods of treatment using the same
Nov, 2027

(4 years from now)

Drugs and Companies using BOCEPREVIR ingredient

Market Authorisation Date: 13 May, 2011

Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food; Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in...

Dosage: CAPSULE;ORAL

More Information on Dosage

VICTRELIS family patents

6

United States

2

Japan

2

New Zealand

2

Canada

2

Australia

2

Taiwan, Province of China

2

European Union

1

Argentina

1

Brazil

1

South Africa

1

Poland

1

Spain

1

Mexico

1

Peru

1

Norway

1

Korea, Republic of

1

China

17. List of Welireg drug patents

Can you believe WELIREG received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9969689 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(11 years from now)

US9908845 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 13, 2026
Orphan Drug Exclusivity (ODE) Aug 13, 2028

Drugs and Companies using BELZUTIFAN ingredient

NCE-1 date: 2025-08-13

Market Authorisation Date: 13 August, 2021

Treatment: Treatment of adult patients with von hippel-lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not r...

Dosage: TABLET;ORAL

More Information on Dosage

WELIREG family patents

10

United States

4

Japan

4

European Union

3

Spain

2

Slovenia

2

Lithuania

2

Hungary

2

Croatia

2

Portugal

2

Poland

2

Taiwan, Province of China

2

RS

2

China

1

Israel

1

Denmark

1

Mexico

1

Australia

1

Hong Kong

1

Uruguay

1

Cuba

1

Singapore

1

Argentina

1

Peru

1

Korea, Republic of

EA

1

EA

1

Canada

1

New Zealand

18. List of Zepatier drug patents

Can you believe ZEPATIER received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7973040 MERCK SHARP DOHME Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
Jul, 2029

(6 years from now)

US8871759 MERCK SHARP DOHME Inhibitors of hepatitis C virus replication
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Dec 9, 2024

Drugs and Companies using ELBASVIR; GRAZOPREVIR ingredient

Market Authorisation Date: 28 January, 2016

Treatment: Treatment of patients infected with hepatitis c virus

Dosage: TABLET;ORAL

More Information on Dosage

ZEPATIER family patents

17

United States

4

China

4

European Union

3

Denmark

3

Hong Kong

3

Slovenia

3

Hungary

3

Croatia

3

Cyprus

3

Spain

3

Korea, Republic of

3

Poland

3

RS

3

Japan

3

ME

2

Israel

2

South Africa

2

Mexico

2

Australia

2

Lithuania

2

Morocco

2

Norway

2

Costa Rica

2

Singapore

2

Colombia

2

Brazil

2

Portugal

2

Malaysia

2

Netherlands

2

Dominican Republic

2

Peru

2

Ecuador

2

Luxembourg

2

Ukraine

2

Nicaragua

EA

2

EA

2

Canada

2

Tunisia

2

New Zealand

1

El Salvador

1

Honduras

1

Argentina

1

Chile

1

Taiwan, Province of China

1

Georgia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in

Drugs made by Meridian Medcl

Drug information about Tricor